John B. Henneman III, Director at Orthofix Medical Inc. (OFIX), bought 5,000 shares at $12.26 ($61K) on 2026-05-07, disclosed to the SEC on 2026-05-08.
Director John B. Henneman III purchased 5,000 shares for $61,295, marking the largest purchase of his career. This move comes as the stock trades near its 52-week low after analysts recently reset price targets to the mid-teens following Q1 2026 results.
OFIX is currently trading at $11.65, down 8.98% over the last 90 days and 31.43% below its 52-week high of $16.99.
Q1 2026 earnings were reported on May 5, 2026, and analysts assigned a US$17.25 price target on May 8, 2026. Additionally, the stock is technically oversold after falling 12.6% in the four weeks leading up to March 16, 2026.
The 90-day net buyer flow is negative at -5.0, and industry insiders have only bought 1.1% of shares in the last 90 days. Recent commentary also highlights execution risk and extended timelines for adjusted EBITDA margin goals.
Something here stands out, but not much.
| Filing → |
| RCM | SELL | 2023-08-09 | $1.7M | — | Filing → |
| ANIK | BUY | 2021-05-20 | $86K | — | Filing → |
| SPNE | SELL | 2020-08-05 | $150K | — | Filing → |